Items tagged with Treatment
Stop TB Partnership's Global Drug Facility jumpstarts access to new drugs for MDR-TB with innovative public-private partnerships (post with simple image)
The initiative will allow countries to access delamanid through the Stop TB Partnership’s Global Drug Facility at a price of US$ 1700 for each full-course treatment of six months’ duration.
Just 2% of people with the severest cases of drug-resistant TB currently have access to new, more effective treatments (post with simple image)
Médecins Sans Frontières released the 4th edition of its report DR-TB Drugs Under the Microscope. The report analyzes the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis.
Advocates call for WHO to update Delamanid Guidance to include children (post with simple image)
On World TB Day, and in light of new evidence of safety in children, advocates called on the World Health Organization to update its 2014 guidance on delamanid to include children.
STREAM Stage 2 Trial begins (post with simple image)
Stage 2 of trial aims to reduce MDR-TB treatment from 24 months to 6 or 9 months.
New Indian guidelines on the use of bedaquiline (post with simple image)
The Indian Ministry of Health and Family Welfare released Guidelines for use of Bedaquiline in RNTCP through conditional access under Programmatic Management of Drug Resistant Tuberculosis in India.
World Health Organization recommends shorter treatment for multidrug-resistant TB (post with simple image)
New World Health Organization recommendations aim to speed up detection and improve treatment outcomes for multidrug-resistant TB through use of a novel rapid diagnostic test and a shorter, cheaper treatment regimen.
Rapid Clinical Advice on new TB drugs in children (post with simple image)
The Sentinel Project’s Advocacy Task Force has developed Rapid Clinical Advice on the use of new TB drugs bedaquiline and delamanid in children.
Call to Action to accelerate access to DR-TB drugs: 2016 update (post with simple image)
The update informs about the general progress in the introduction of bedaquiline and delamanid in TB programs worldwide and reports on the requests made in the Call to Action issued in March 2015.
“Towards Ending the Neglect?” DNDi releases update on its paediatric HIV programme (post with simple image)
As the International AIDS Conference kicks off in Durban, the Drugs for Neglected Diseases initiative (DNDi) has released an update on its efforts to develop optimal child-adapted antiretroviral formulations. This document details some recent progress towards its final goal of developing “4-in-1” fixed-dose combinations using the World Health Organization (WHO) recommended treatment regimen for infants and young children. DNDi’s update also discusses some promising developments for treatment for children living with both HIV and tuberculosis (TB).
New clinical practice guidelines: Treatment of drug-susceptible TB (post with simple image)
Jointly developed by the American Thoracic Society, U.S. Centers for Disease Control and Prevention and Infectious Diseases Society of America.
Page 50 of 52 · Total posts: 0←First 49 50 51 Last→